Rigel update above views

 

• Preliminary fourth quarter 2023 total revenue of approximately $35.7 million which includes record TAVALISSE® net product sales of $25.7 million and REZLIDHIA® net product sales of $3.9 million
• Strategic alliance with MD Anderson to advance REZLIDHIA in AML and other cancers
• Collaboration with CONNECT to evaluate REZLIDHIA in a Phase 2 clinical trial in glioma

https://www.prnewswire.com/news-releases/rigel-pharmaceuticals-provides-business-update-302027953.html